drugset / Trial / NCT03669185

Pentaerithrityl Tetranitrate (PETN) for Secondary Prevention of Intrauterine Growth Restriction

NCT03669185 ↗

Phase 3 Unknown 324 enrolled Jena University Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Approximately 10% of all pregnancies experience mal perfusion of the placenta resulting in fetal growth restriction (FGR) of the fetus. FGR is the most important cause of perinatal mortality and morbidity. Impaired placental function determined by insufficient transformation of the uterine arteries and mal-perfusion of the placenta is the leading cause of FGR. So far, there is no treatment option for pregnancies complicated by FGR and the clinical management is restricted to close monitoring, assessing for the optimal time point of delivery of the fetus threatened by intrauterine death. In a pilot study a risk reduction of 38% for the development of severe FGR and FGR or death could be demonstrated by giving the organic nitrate pentaerithrityl-tetranitrate (PETN) to patients recognized at risk for FGR by impaired uterine artery Doppler at mid gestation (Schleussner, 2014). To confirm these results this prospective randomized placebo controlled double-blinded multicentre trial, was initiated.

Timeline

Start
2017-07-26
Primary completion
2020-07-31
Completion
2021-10-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pentaeritrithyl tetranitrate Small molecule 50 mg —